Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Plos One|December 19, 2013
First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsKlaus Mross, Heike Richly, Richard Fischer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.Cancer Chemotherapy and Pharmacology|June 29, 2016
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumorsKlaus Mross, Heike Richly, Annette Frost, et al.Targeted Oncology|October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.Vascular Cell|August 2, 2011
Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancerKlaus Mross, Annette Frost, Max E Scheulen, et al.Targeted Oncology|April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsKlaus Mross, Martin Stefanic, Daniela Gmehling, et al.Breast Cancer Research and Treatment|January 2, 2004
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2Marc Azemar, Sirus Djahansouzi, Elke Jäger, et al.Pageof 4